A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 352 participants.

Also called NCT07352969

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 352 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07352969
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07352969. Randomized; quadruple masking; primary purpose treatment. Start 2026-02-05 (actual); primary completion 2029-03-27 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients
Condition
Hypertension
Intervention (Drug)
IBI3016
Intervention (Other)
Placebo
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07352969
Content hash
109e83580dfb373d7309ccadbe58c1ff1aa7391396fb704d76a0f90669fa52ca